Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Shah MA, Mayer S, Emlen F, Sholle E, Christos P, Cushing M, et al. Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. JAMA Netw Open. 2020;3(9):e2023121.

Haider S, Tyekucheva S, Prandi D, Fox NS, Ahn J, Xu AW, et al. Systematic Assessment of Tumor Purity and Its Clinical Implications. JCO Precis Oncol. 2020;4.

Chung EY, McIlroy K, Fung C, Seshan SV, Moran S, Coleman PL. Glomerular, Mesangial, and Tubular Cytoplasmic Fibrillary Inclusions in a Patient with Light-Chain Proximal Tubulopathy. Nephron. 2020;144(4):190-194.

Droll SH, Hsu Y-, Drake SK, Kim A, Wang W, Calvo KR, et al. Differential processing of high-molecular-weight kininogen during normal pregnancy. Rapid Commun Mass Spectrom. 2020;34 Suppl 1:e8552.

Green DA, Zucker J, Westblade LF, Whittier S, Rennert H, Velu P, et al. Clinical Performance of SARS-CoV-2 Molecular Tests. J Clin Microbiol. 2020;58(8).

Hwang I, Pan H, Yao J, Elemento O, Zheng H, Paik J. CIC is a critical regulator of neuronal differentiation. JCI Insight. 2020;5(9).

Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020;80(12):1012-1023.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25(2):140-149.

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.

Basourakos SP, Kasabwala K, Silich R, Mosquera JM, Choi B. Neurofibroma originating from a urachal mass. Can J Urol. 2020;27(5):10407-10410.